|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
6.670 USD |
-0.89% | -2.63% | -10.23% | |
Published on 06/17/2025 at 08:27
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Lifecore Biomedical Receives Remaining $10 Million for Sale of Isolator Filler Ahead of Schedule |
Jun. 12 |
MT |
|
Lifecore Biomedical Names Mark Dafonseca Chief Commercial Officer |
May. 27 |
RE |
|
Lifecore Biomedical, Inc. Appoints Mark DaFonseca as Chief Commercial Officer |
May. 27 |
CI |
|
William Blair Initiates Coverage on Lifecore Biomedical With Outperform Rating |
May. 21 |
MT |
|
Lifecore Biomedical, Inc. Appoints Thomas D. Salus as Chief Legal and Administration Officer |
Apr. 14 |
CI |
|
Sector Update: Health Care Stocks Fall Late Afternoon |
Apr. 04 |
MT |
|
Top Midday Decliners |
Apr. 04 |
MT |
|
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results |
Apr. 03 |
RE |
|
Lifecore Biomedical Q3 Swings to Loss, Revenue Lower |
Apr. 03 |
MT |
|
Lifecore Biomedical, Inc., Q3 2025 Earnings Call, Apr 03, 2025 |
Apr. 03 |
|
|
Lifecore Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 23, 2025 |
Apr. 03 |
CI |
|
Lifecore Biomedical, Inc. Reiterates Financial Guidance for the Full Fiscal Year 2025 |
Apr. 03 |
CI |
|
Humanetics Selects Lifecore Biomedical To Deliver CDMO Services Supporting Development Of BIO 300 For The Prevention Of Acute Radiation Syndrome |
Mar. 17 |
RE |
|
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome |
Mar. 17 |
CI |
|
Lifecore Biomedical, Inc. Enters into a Sales Agreement |
Jan. 07 |
CI |
|
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday |
Jan. 03 |
MT |
|
Sector Update: Health Care |
Jan. 03 |
MT |
|
Tranche Update on Lifecore Biomedical, Inc.’s Equity Buyback Plan announced on July 14, 2010. |
Jan. 02 |
CI |
|
Lifecore Biomedical, Inc., Q2 2025 Earnings Call, Jan 02, 2025 |
Jan. 02 |
|
|
Lifecore Biomedical Swings to Fiscal Q2 Loss, Higher Revenue |
Jan. 02 |
MT |
|
Lifecore Biomedical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 24, 2024 |
Jan. 02 |
CI |
|
Nirsum Labs, Inc. Selects Lifecore Biomedical, Inc. to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment |
Dec. 19 |
CI |
|
Lifecore Biomedical Amends, Extends Credit Facility |
Nov. 26 |
MT |
|
Lifecore Biomedical, Inc. Provides Earnings Guidance for the Year 2025 |
Nov. 21 |
CI |
|
Lifecore Biomedical, Inc. – Analyst/Investor Day |
Nov. 21 |
LFCR: Dynamic Chart
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
More about the company
Buy
Average target price
10.00USD
Spread / Average Target
+49.93%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
